Replimune Group, Inc.

Listed Company

REPLCIK 0001737953NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)DelawareFY ends Mar 31

Period

FY 2025

Revenue

—

Net Income

—

Total Assets

$551.33M

Equity

$415.84M

Shares Out

82.57M

Op. Cash Flow

$-192.25M

Business

Replimune Group, Inc. is a clinical‑stage biotechnology company developing oncolytic immunotherapies that activate the immune system to treat cancer. It offers proprietary RPx platform product candidates—HSV‑1–based oncolytic viruses including lead candidate RP1 (vusolimogene oderparepvec) and follow‑ons RP2 and RP3—designed to replicate in tumors, induce immunogenic cell death, and deliver immune‑activating payloads alone or in combination with checkpoint inhibitors. Key business areas include clinical development, in‑house viral biologics manufacturing, and strategic collaborations with pharmaceutical partners. The company runs global clinical trials and plans U.S. commercialization while pursuing partnerships and distribution in other regions, with therapies administered by direct tumor injection in outpatient and image‑guided settings.

Summary from filing dated 2025-05-22

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31	FY 2021 2021-03-31
Research and development	189	175	127	80	57
Selling, general and administrative	72	60	51	39	23
Total operating expenses	262	235	177	118	80
Loss from operations	−262	−235	−177	−118	−80
Research and development incentives	2	2	3	3	3
Investment income	21	23	10	390,000	916,000
Interest expense on finance lease liability	−2	−2	−2	−2	−2
Interest expense on debt obligations	−6	−4	−2	0	−818,000
Other (expense) income	−202,000	771,000	−6	−1	−665,000
Total other income, net	15	19	3	278,000	−915,000
Loss before income taxes	−247	−215	−174	−118	—
Income tax provision	500,000	400,000	300,000	0	—
Net loss	−247	−216	−174	−118	−81
Net loss per common share, basic (in dollars per share)	−3.07	−3.24	−2.99	−2.26	−1.75
Net loss per common share, diluted (in dollars per share)	−3.07	−3.24	−2.99	−2.26	−1.75
Weighted average common shares outstanding, basic (in shares)	81	67	58	52	46
Weighted average common shares outstanding, diluted (in shares)	81	67	58	52	46

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31	FY 2021 2021-10-31
Cash and cash equivalents	111	74	147	106	—
Short-term investments	373	346	437	290	—
Research and development incentives receivable	4	5	3	3	—
Prepaid expenses and other current assets	8	8	6	5	—
Total current assets	496	434	593	404	—
Property, plant and equipment, net	14	10	7	8	—
Restricted cash	2	2	2	2	—
Other non-current assets	1	0	—	—	—
Right-to-use assetoperating leases	4	5	5	6	400,000
Right-to-use assetfinancing leases	35	37	40	42	—
Total assets	551	488	647	461	—
Accounts payable	12	3	5	4	—
Accrued expenses and other current liabilities	46	34	25	13	—
Operating lease liabilities, current	1	1	1	1	—
Financing lease liabilities, current	3	3	3	3	—
Total current liabilities	62	40	34	21	—
Operating lease liabilities, non-current	3	4	4	5	—
Financing lease liabilities, non-current	23	23	24	24	—
Long term debt, net of discount	46	45	29	0	—
Other liabilities, non-current	941,000	786,000	472,000	0	—
Total liabilities	135	113	91	50	—
Commitments and contingencies (Note 13)	—	—	—	—	—
Common stock, $0.001 par value; 150,000,000 shares authorized as of March 31, 2025 and March 31, 2024; 77,085,024 and 61,415,105 shares issued and outstanding as of March 31, 2025 and March 31, 2024, respectively	77,000	61,000	57,000	47,000	—
Additional paid-in capital	1,359	1,071	1,035	723	—
Accumulated deficit	−949	−701	−485	−311	—
Accumulated other comprehensive income	5	5	6	−973,000	—
Total stockholders equity	416	375	555	411	—
Total liabilities and stockholders equity	551	488	647	461	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31	FY 2021 2021-03-31
Net loss	−247	−216	−174	−118	−81
Stock-based compensation expense	35	34	28	24	12
Depreciation and amortization	4	3	2	2	2
Net amortization of premiums and discounts on short-term investments	−9	−12	−6	2	1
Noncash interest expense	2	1	494,000	0	181,000
Unrealized foreign currency transaction losses	−201,000	−771,000	6	0	—
Research and development incentives receivable	1	−2	−61,000	−247,000	325,000
Prepaid expenses and other current assets	−252,000	−2	−1	−815,000	−2
Operating lease, right-of-use-asset	683,000	615,000	225,000	99,000	447,000
Finance lease, right-of-use-asset	2	2	2	2	2
Other non-current assets	−1	0	—	—	—
Accounts payable	10	−3	2	1	−1
Accrued expenses and other current liabilities	12	9	11	5	3
Operating lease liabilities	−720,000	−620,000	−238,000	−73,000	−340,000
Other non-current liabilities	155,000	314,000	472,000	0	—
Net cash used in operating activities	−192	−185	−128	−82	−61
Purchases of property, plant and equipment and software capitalization	−7	−6	−2	—	—
Purchase of short-term investments	−404	−490	−583	−256	−392
Proceeds from sales and maturities of short-term investments	386	592	443	256	206
Net cash (used in) provided by investing activities	−24	97	−143	−2	−189
Proceeds from issuance of common stock, net of underwriting fees and offering costs	156	0	150	0	286
Proceeds from issuance of prefunded warrants to purchase common stock, net of underwriting fees and offering costs	97	0	93	0	92
Proceeds from long-term debt	0	15	28	0	—
Principal payment of finance lease obligation	−599,000	−476,000	−365,000	−264,000	−145,000
Proceeds from exercise of stock options	267,000	2	3	7	6
Net cash provided by financing activities	252	16	311	7	372
Effect of exchange rate changes on cash, cash equivalents and restricted cash	315,000	−86,000	−109,000	818,000	721,000
Net increase (decrease) in cash, cash equivalents and restricted cash	37	−72	41	−77	123
Cash paid during the period for interest	4	3	1	0	636,000
Cash paid for income taxes	105,000	300,000	0	55,000	0
Purchases of property and equipment included in accounts payable	171,000	101,000	103,000	415,000	98,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro